MannKind to Webcast Investor Day Presentations (PR Newswire)

Recently...   •   Stock Market Alert's Stocks to Watch! April 5, 2006   •   Upcoming Beckman Coulter Investor Events in 2006   •   MannKind to Webcast Investor Day Presentations   •   Save the World Air Retains CCG Investor Relations   •   Spectrem Affluent Investor Index(TM) Falls 3 Points in March to 10 -- First Decline Since October 2005   •   NewMarket Technology Inc. Changes Conference Call Phone Number to Accommodate Significant Increase in Investor Interest   •   PC World Magazine Calls AirDefense Personal Indispensible   •   Epicor(R) Reports Preliminary Fourth Quarter and Fiscal Year 2005 Earnings   •   ActivIdentity Appoints Mark J. Lustig as Chief Financial Officer   •   Jones Lang LaSalle Reports Record Earnings; 2005 Net Income of $104 Million, $3.12 Per Share Archive   •   April 2006   •   February 2006   •   December 2005   •   November 2005   •   March 2005   •   January 2005   •   October 2004   •   September 2004   •   August 2004   MannKind Corporation (Nasdaq: MNKD - News), focused on discovering, developing and commercializing treatments for diabetes and cancer, announced today that management will webcast its meeting with investors and analysts on Wednesday, April 19, 2006 from 8:30am ET to 12:00pm ET via the Investor Relations section of the Company's website at www.mannkindcorp.com. An audio replay of the presentations will be available for 14 days. Alfred E. Mann, Chairman of the Board and Chief Executive Officer, Hakan S. Edstrom, President and Chief Operating Officer, and members of the executive leadership team will provide an overview of the Company, clinical developments of the Technosphere Insulin System, and the progress of MannKind's therapies for solid tumor cancers. A special presentation on the changes in diabetes care will be given by Dr. Irl Hirsch, Professor of Medicine and the Medical Director of the Diabetes Care Center, University of Washington Medical Center and the 2004 recipient of the Outstanding Physician Clinician in Diabetes Care Award by the American Diabetes Association. In addition, management will announce and discuss the results from Study 101 comparing mealtime use of Technosphere Insulin to mealtime use of rapid-acting, subcutaneous insulin in approximately 90 patients with type 1 diabetes. About MannKind Corporation MannKind Corporation (Nasdaq: MNKD - News) focuses on the discovery, development and commercialization of therapeutic products for diseases such as diabetes and cancer. Its lead investigational product candidate, the Technosphere® Insulin System, is currently in phase 3 clinical trials in the U.S. and Europe to study its safety and efficacy in the treatment of diabetes. For more information on MannKind Corporation and its technology, visit www.mannkindcorp.com. -------------------------------------------------------------------------------- Source: MannKind Corporation Source: PR Newswire All trademarks and copyrighted information contained herein are the property of their respective owners.